| Autor: |
Bashiri, Fahad A., Hundallah, Khaled, Abukhaled, Musaad, Alyahya, Mossaed Mohammed, Al Futaisi, Amna, Alshowaeir, Daniah, Al Tawari, Asmaa, Abdullah, Shaker, Maaz, Ata Ur Rehman, AlShamsi, Eman Taryam, Alshuaibi, Walaa, Alotaibi, Faisal, Aldhalaan, Hesham |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology; 2024, p1-2, 2p |
| Abstrakt: |
This correction notice from the journal "Frontiers in Oncology" addresses an error in the FDA approval status of mirdametinib in the article "Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations." The correction clarifies that mirdametinib, along with other MEK inhibitors, is being investigated for the treatment of NF1-associated plexiform neurofibromas. The authors acknowledge the error and emphasize that it does not impact the scientific conclusions of the original article. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
